The commercialization of the biomedical sciences: (mis)understanding bias

被引:5
作者
de Melo-Martin, Inmaculada [1 ]
机构
[1] Weill Cornell Med Coll, 407 E 61st,RR-212, New York, NY 10065 USA
来源
HISTORY AND PHILOSOPHY OF THE LIFE SCIENCES | 2019年 / 41卷 / 03期
关键词
Bias; Industry bias; Commercialization of science; Research agenda; Non-epistemic values in science; RANDOMIZED-CONTROLLED-TRIALS; SOCIAL DETERMINANTS; DRUG TRIALS; INDUSTRY; HEALTH; PUBLICATION; US; METAANALYSES; CONSEQUENCES; CONCLUSIONS;
D O I
10.1007/s40656-019-0274-x
中图分类号
N09 [自然科学史]; B [哲学、宗教];
学科分类号
01 ; 0101 ; 010108 ; 060207 ; 060305 ; 0712 ;
摘要
The growing commercialization of scientific research has raised important concerns about industry bias. According to some evidence, so-called industry bias can affect the integrity of the science as well as the direction of the research agenda. I argue that conceptualizing industry's influence in scientific research in terms of bias is unhelpful. Insofar as industry sponsorship negatively affects the integrity of the research, it does so through biasing mechanisms that can affect any research independently of the source of funding. Talk about industry bias thus offers no insight into the particular epistemic shortcomings at stake. If the concern is with the negative effects that industry funding can have on the research agenda, conceptualizing this influence as bias obscures the ways in which such impact is problematic and limits our ability to offer solutions that can successfully address the concerns raised by the growing role of private funding in science.
引用
收藏
页数:17
相关论文
共 103 条
[1]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[2]  
Angell M., 2004, TRUTH DRUG CO THEY D
[3]  
[Anonymous], 2008, REV ESP SALUD PUBLIC
[4]  
[Anonymous], 2017, CURRENT CONTROVERSIE
[5]  
[Anonymous], BMJ BRIT MED J
[6]   Conflict of interest in industry-sponsored economic evaluations: real or imagined? [J].
Barbieri M. ;
Drummond M.F. .
Current Oncology Reports, 2001, 3 (5) :410-413
[7]   Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov [J].
Bourgeois, Florence T. ;
Murthy, Srinivas ;
Mandl, Kenneth D. .
ANNALS OF INTERNAL MEDICINE, 2010, 153 (03) :158-U48
[8]   Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis [J].
Boutron, I ;
Tubach, F ;
Giraudeau, B ;
Ravaud, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (08) :1062-1070
[9]   Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary Outcomes [J].
Boutron, Isabelle ;
Dutton, Susan ;
Ravaud, Philippe ;
Altman, Douglas G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (20) :2058-2064
[10]   The Social Determinants of Health: It's Time to Consider the Causes of the Causes [J].
Braveman, Paula ;
Gottlieb, Laura .
PUBLIC HEALTH REPORTS, 2014, 129 :19-31